Ionis Pharmaceuticals Company Profile (NASDAQ:IONS)

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company's Ionis Core segment is developing a drug discovery platform. The Company's Akcea Therapeutics segment consists of the operations of its subsidiary, Akcea Therapeutics, Inc., which develops and commercializes drugs for cardiometabolic disorders. The Company is developing transformational drugs, which include nusinersen, IONIS-TTR and volanesorsen that are designed to treat patients with orphan diseases. In addition to its Phase III programs, the Company has a pipeline of drugs in Phase II development, which includes IONIS-FXI and IONIS-APO(a)-L. Its Phase II pipeline includes drugs to treat patients with severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases.

Industry, Sector and Symbol:

Sector: Medical
Industry: Drug Manufacturers - Other
Sub-Industry: Biotechnology
Exchange: NASDAQ
Symbol: IONS
CUSIP: 46433010

Key Metrics:

Previous Close: $36.20
50 Day Moving Average: $32.54
200 Day Moving Average: $32.40
52-Week Range: $19.59 - $65.34
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -35.84
P/E Growth: -0.80
Market Cap: $4.41B
Outstanding Shares: 120,919,000
Beta: 2.1

Profitability:

Net Margins: -128.94%
Return on Equity: -126.88%
Return on Assets: -25.00%

Debt:

Debt-to-Equity Ratio: 3.63%
Current Ratio: 6.28%
Quick Ratio: 6.21%

Additional Links:

Companies Related to Ionis Pharmaceuticals:

Consensus Ratings for Ionis Pharmaceuticals (NASDAQ:IONS) (?)

Ratings Breakdown:	1 Sell Rating, 7 Hold Ratings, 4 Buy Ratings
Consensus Rating:	Hold (Score: 2.25)
Consensus Price Target:	$38.78 (7.12% upside)

Analysts' Ratings History for Ionis Pharmaceuticals (NASDAQ:IONS)

Show:

Date	Firm	Action	Rating	Price Target
9/28/2016	Janney Montgomery Scott	Initiated Coverage	Buy
9/26/2016	Piper Jaffray Cos.	Reiterated Rating	Overweight	$46.00
9/11/2016	Wells Fargo & Co.	Reiterated Rating	Buy
8/13/2016	Cowen and Company	Reiterated Rating	Market Perform
8/11/2016	Leerink Swann	Reiterated Rating	Hold	$36.00
8/2/2016	Barclays PLC	Boost Price Target	Equal Weight	$26.00 -> $41.00
8/2/2016	Morgan Stanley	Initiated Coverage	Equal -> Equal Weight	$37.00 -> $37.00
8/1/2016	BMO Capital Markets	Boost Price Target	Market Perform	$25.00 -> $40.00
8/1/2016	Needham & Company LLC	Boost Price Target	Buy	$55.00 -> $64.00
7/15/2016	Jefferies Group	Reiterated Rating	Underperform	$12.00
5/29/2016	JPMorgan Chase & Co.	Reiterated Rating	Hold
2/22/2016	Goldman Sachs Group Inc.	Lower Price Target		$65.00 -> $48.00
6/22/2015	Deutsche Bank AG	Set Price Target	Buy	$78.00
3/2/2015	Stifel Nicolaus	Downgrade	Buy -> Hold	$66.00
3/2/2015	Brean Capital	Downgrade	Buy -> Hold
12/9/2014	Laidlaw	Boost Price Target		$65.00

(Data available from 9/29/2014 forward)

Earnings History for Ionis Pharmaceuticals (NASDAQ:IONS)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/7/2016
8/9/2016	Q216	($0.52)	($0.47)	$38.52 million	$38.50 million	View	N/A
5/4/2016	Q116	($0.50)	($0.52)	$36.21 million	$36.90 million	View	N/A
2/25/2016	Q415	($0.47)	($0.59)	$49.32 million	$51.60 million	View	Listen
11/9/2015	Q315	($0.31)	($0.30)	$52.93 million	$49.10 million	View	N/A
8/4/2015	Q215	$0.29	$0.29	$114.93 million	$120.40 million	View	N/A
5/5/2015	Q115	($0.19)	($0.14)	$52.74 million	$62.60 million	View	N/A
2/27/2015	Q414	$0.12	$0.25	$74.58 million	$84.90 million	View	N/A
11/7/2014	Q314	($0.20)	($0.23)	$45.79 million	$44.10 million	View	N/A
8/4/2014	Q214	($0.12)	($0.10)	$45.60 million	$57.08 million	View	N/A
5/6/2014	Q114	($0.23)	($0.27)	$35.12 million	$28.20 million	View	N/A
2/28/2014	Q413	($0.17)	($0.21)	$34.20 million	$42.25 million	View	N/A
11/5/2013	Q313	($0.27)	($0.21)	$19.82 million	$23.60 million	View	N/A
8/6/2013	Q2 2013	($0.21)	($0.09)	$26.76 million	$38.10 million	View	Listen
5/7/2013	Q1 2013	($0.02)	($0.02)	$45.24 million	$43.36 million	View	Listen
2/28/2013	Q4 2012	($0.23)	($0.03)	$15.78 million	$19.90 million	View	Listen
11/6/2012	Q312	($0.26)	($0.37)	$23.11 million	$11.60 million	View	N/A
8/6/2012		($0.08)	($0.01)			View	N/A
5/8/2012		($0.28)	($0.24)			View	N/A
2/29/2012		($0.13)	($0.20)			View	N/A
11/7/2011		($0.20)	($0.27)			View	N/A
8/4/2011		($0.22)	($0.18)			View	N/A
5/5/2011		($0.19)	($0.20)			View	N/A
2/28/2011		($0.22)	($0.14)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)

Current Year EPS Consensus Estimate: $-1.06 EPS
Next Year EPS Consensus Estimate: $-1.01 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q2 2016	2	($0.50)	($0.45)	($0.48)
Q3 2016	2	($0.02)	$0.18	$0.08
Q4 2016	2	($0.29)	($0.08)	($0.19)

(Data provided by Zacks Investment Research)

Dividend History for Ionis Pharmaceuticals (NASDAQ:IONS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Ionis Pharmaceuticals (NASDAQ:IONS)

Insider Ownership Percentage: 1.86%
Institutional Ownership Percentage: 89.58%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/21/2016	Stanley T Crooke	Chairman	Sell	22,000	$35.50	$781,000.00
9/1/2016	B Lynne Parshall	COO	Sell	12,500	$29.88	$373,500.00
5/31/2016	Frederick T Muto	Director	Sell	12,500	$22.31	$278,875.00
4/6/2016	Patrick R O'neil	SVP	Sell	1,000	$45.00	$45,000.00
4/6/2016	Stanley T Crooke	CEO	Sell	11,000	$46.13	$507,430.00
3/31/2016	Stanley T Crooke	CEO	Sell	11,000	$40.74	$448,140.00
3/23/2016	Patrick R O'neil	SVP	Sell	1,000	$45.40	$45,400.00
1/19/2016	B Lynne Parshall	COO	Sell	5,192	$41.46	$215,260.32
1/19/2016	C Frank Bennett	SVP	Sell	2,110	$41.46	$87,480.60
1/19/2016	Elizabeth L. Hougen	CFO	Sell	1,899	$41.46	$78,732.54
1/19/2016	Sarah Boyce	insider	Sell	872	$41.46	$36,153.12
1/19/2016	Stanley T. Crooke	CEO	Sell	13,401	$41.46	$555,605.46
1/5/2016	Stanley T. Crooke	CEO	Sell	5,500	$62.10	$341,550.00
1/4/2016	B Lynne Parshall	COO	Sell	809	$61.05	$49,389.45
1/4/2016	Brett P. Monia	SVP	Sell	127	$61.00	$7,747.00
1/4/2016	Stanley T. Crooke	CEO	Sell	11,000	$61.05	$671,550.00
12/16/2015	C Frank Bennett	SVP	Sell	7,909	$57.41	$454,055.69
12/1/2015	Patrick R. O'neil	SVP	Sell	1,000	$61.50	$61,500.00
11/11/2015	Joseph Klein III	Director	Sell	6,875	$64.18	$441,237.50
11/10/2015	C Frank Bennett	SVP	Sell	5,000	$64.00	$320,000.00
11/6/2015	C Frank Bennett	SVP	Sell	5,000	$56.00	$280,000.00
11/3/2015	Patrick R. O'neil	SVP	Sell	1,000	$51.95	$51,950.00
10/23/2015	Stanley T. Crooke	CEO	Sell	44,000	$43.85	$1,929,400.00
10/2/2015	B Lynne Parshall	COO	Sell	12,436	$40.75	$506,767.00
7/6/2015	B Lynne Parshall	COO	Sell	6,218	$57.01	$354,488.18
7/6/2015	Stanley T Crooke	CEO	Sell	5,000	$57.01	$285,050.00
7/1/2015	B Lynne Parshall	COO	Sell	6,218	$57.56	$357,908.08
7/1/2015	Stanley T Crooke	CEO	Sell	6,175	$57.56	$355,433.00
6/8/2015	Brett P Monia	SVP	Sell	7,600	$66.22	$503,272.00
4/7/2015	B Lynne Parshall	COO	Sell	5,565	$63.07	$350,984.55
4/7/2015	Stanley T Crooke	CEO	Sell	22,377	$63.07	$1,411,317.39
3/24/2015	C Frank Bennett	SVP	Sell	15,000	$70.61	$1,059,150.00
3/19/2015	Elizabeth L Hougen	CFO	Sell	10,000	$73.33	$733,300.00
3/19/2015	Patrick R O'neil	SVP	Sell	30,525	$74.85	$2,284,796.25
3/2/2015	Joseph H Wender	Director	Sell	7,000	$65.97	$461,790.00
1/27/2015	Stanley T Crooke	CEO	Sell	11,000	$72.93	$802,230.00
1/16/2015	B Lynne Parshall	COO	Sell	4,093	$67.96	$278,160.28
1/16/2015	Elizabeth L Hougen	CFO	Sell	1,291	$67.96	$87,736.36
1/16/2015	Richard S Geary	SVP	Sell	1,543	$67.96	$104,862.28
1/16/2015	Stanley T Crooke	CEO	Sell	9,054	$67.96	$615,309.84
1/9/2015	Stanley T Crooke	CEO	Sell	11,000	$73.57	$809,270.00
1/7/2015	Stanley T Crooke	CEO	Sell	22,000	$67.04	$1,474,880.00
1/2/2015	B Lynne Parshall	COO	Sell	11,200	$62.12	$695,744.00
1/2/2015	Patrick R O'neil	SVP	Sell	1,500	$62.12	$93,180.00
12/1/2014	Patrick R O'neil	SVP	Sell	1,500	$51.21	$76,815.00
11/3/2014	Patrick R O'neil	SVP	Sell	1,500	$46.17	$69,255.00
10/30/2014	B Lynne Parshall	COO	Sell	11,071	$45.12	$499,523.52
10/23/2014	Stanley T Crooke	CEO	Sell	14,600	$42.22	$616,412.00
10/3/2014	Stanley T Crooke	CEO	Sell	36,000	$38.52	$1,386,720.00
10/1/2014	Patrick R O'neil	SVP	Sell	1,500	$38.04	$57,060.00
10/1/2014	Stanley T Crooke	CEO	Sell	20,000	$37.91	$758,200.00
8/27/2014	C Frank Bennett	SVP	Sell	5,000	$40.53	$202,650.00
8/13/2014	Stanley T Crooke	CEO	Sell	15,500	$35.45	$549,475.00
8/12/2014	Patrick R O'neil	SVP	Sell	1,500	$35.00	$52,500.00
8/1/2014	Stanley T Crooke	CEO	Sell	16,000	$30.53	$488,480.00
7/31/2014	Brett P Monia	SVP	Sell	79	$31.50	$2,488.50
7/1/2014	Patrick R O'neil	SVP	Sell	1,500	$35.33	$52,995.00
7/1/2014	Stanley T Crooke	CEO	Sell	17,500	$35.57	$622,475.00
6/23/2014	C Frank Bennett	SVP	Sell	11,200	$36.78	$411,936.00
6/19/2014	Stanley T Crooke	CEO	Sell	11,000	$35.10	$386,100.00
6/10/2014	Stanley T Crooke	CEO	Sell	11,000	$33.46	$368,060.00
6/2/2014	Frederick T Muto	Director	Sell	10,000	$28.59	$285,900.00
4/2/2014	Stanley Crooke	CEO	Sell	8,800	$43.65	$384,120.00
1/30/2014	B Lynne Parshall	COO	Sell	89,510	$49.49	$4,429,849.90
1/24/2014	Joseph Klein III	Director	Sell	10,313	$48.66	$501,830.58
1/22/2014	Joseph Wender	Director	Sell	10,000	$50.98	$509,800.00
1/22/2014	Richard Geary	SVP	Sell	22,200	$50.05	$1,111,110.00
1/16/2014	B Lynne Parshall	COO	Sell	1,641	$47.08	$77,258.28
1/16/2014	Stanley Crooke	CEO	Sell	3,527	$47.08	$166,051.16
1/8/2014	Richard Geary	SVP	Sell	15,000	$40.45	$606,750.00
1/8/2014	Stanley Crooke	CEO	Sell	12,500	$40.05	$500,625.00
1/2/2014	Stanley Crooke	CEO	Sell	31,500	$39.35	$1,239,525.00
12/26/2013	B Lynne Parshall	COO	Sell	37,811	$40.91	$1,546,848.01
12/24/2013	B Lynne Parshall	COO	Sell	70,000	$41.49	$2,904,300.00
12/20/2013	Joseph Wender	Director	Sell	19,731	$39.58	$780,952.98
12/5/2013	C Frank Bennett	SVP	Sell	10,000	$39.92	$399,200.00
11/26/2013	Joseph Wender	Director	Sell	10,000	$36.63	$366,300.00
9/20/2013	B Lynne Parshall	COO	Sell	90,000	$35.43	$3,188,700.00
9/20/2013	Brett Monia	SVP	Sell	68,281	$34.21	$2,335,893.01
9/20/2013	Stanley Crooke	CEO	Sell	58,740	$35.19	$2,067,060.60
9/19/2013	C Frank Bennett	SVP	Sell	10,000	$35.02	$350,200.00
9/11/2013	B Lynne Parshall	COO	Sell	63,505	$31.04	$1,971,195.20
9/9/2013	C Frank Bennett	SVP	Sell	10,000	$30.23	$302,300.00
9/4/2013	Patrick R O'neil	SVP	Sell	2,500	$27.09	$67,725.00
8/26/2013	Brett Monia	SVP	Sell	2,909	$25.58	$74,412.22
8/9/2013	Joseph Klein III	Director	Sell	18,750	$28.22	$529,125.00
7/23/2013	Stanley T Crooke	COO	Sell	11,500	$30.00	$345,000.00
7/22/2013	Stanley T Crooke	CEO	Sell	62,200	$30.50	$1,897,100.00
7/17/2013	Stanley T Crooke	CEO	Sell	49,300	$33.12	$1,632,816.00
7/12/2013	Stanley T Crooke	CEO	Sell	90,000	$31.75	$2,857,500.00
7/11/2013	Richard S Geary	SVP	Sell	9,000	$31.90	$287,100.00
7/9/2013	Richard S Geary	SVP	Sell	66,163	$30.03	$1,986,874.89
7/9/2013	Stanley T Crooke	CEO	Sell	109,172	$26.69	$2,913,800.68
7/3/2013	Richard S Geary	SVP	Sell	5,000	$29.02	$145,100.00
7/1/2013	Stanley T Crooke	CEO	Sell	50,683	$27.65	$1,401,384.95
6/26/2013	Stanley T Crooke	CEO	Sell	90,000	$26.73	$2,405,700.00
6/25/2013	Richard S Geary	SVP	Sell	47,049	$26.20	$1,232,683.80
6/20/2013	Joseph H Wender	Director	Sell	5,447	$20.93	$114,005.71
6/11/2013	Brett P Monia	SVP	Sell	9,375	$23.76	$222,750.00
5/30/2013	Frederick T Muto	Director	Sell	10,000	$21.96	$219,600.00
1/16/2013	Stanley T Crooke	CEO	Sell	1,460	$14.00	$20,440.00

(Data available from 1/1/2013 forward)

Latest Headlines for Ionis Pharmaceuticals (NASDAQ:IONS)

Date	Headline
	Ionis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives Lifetime Achievement Award from the Oligonucleotide Therapeutics Society (NASDAQ:IONS) finance.yahoo.com - September 28 at 10:31 AM
	Piper Jaffray Comments on Ionis Pharmaceuticals Inc (IONS) Following Nusinersen NDA Filing - Smarter Analyst (NASDAQ:IONS) www.smarteranalyst.com - September 27 at 10:17 AM
	3 Stocks That Could Make You Rich (NASDAQ:IONS) www.fool.com - September 27 at 10:17 AM
	Biogen : Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for Spinal Muscular Atrophy (NASDAQ:IONS) www.4-traders.com - September 26 at 5:46 PM
	Piper Jaffray Comments on Ionis Pharmaceuticals Inc (IONS) Following Nusinersen NDA Filing (NASDAQ:IONS) www.smarteranalyst.com - September 26 at 5:46 PM
	HC Trending Hot Stocks! Amphastar Pharmaceuticals Inc (AMPH), Ionis Pharmaceuticals Inc (NASDAQ:IONS) - share market updates (press release) (NASDAQ:IONS) sharemarketupdates.com - September 26 at 10:16 AM
	IONIS PHARMACEUTICALS INC Files SEC form 8-K, Other Events (NASDAQ:IONS) biz.yahoo.com - September 23 at 5:20 PM
	Ionis Pharmaceuticals Inc (NASDAQ:IONS) & Pacira Pharmaceuticals Inc (NASDAQ:PCRX) Watch List - Money News (NASDAQ:IONS) www.newsismoney.com - September 23 at 8:36 AM
	Ionis Pharmaceuticals Inc (NASDAQ:IONS) & Goodyear Tire & Rubber Co (NASDAQ:GT) Watch List - Money News (NASDAQ:IONS) www.newsismoney.com - September 23 at 8:36 AM
	Stock Update (NASDAQ:IONS): Ionis Pharmaceuticals Inc's Akcea Announces Publication in The Lancet of Clinical ... - Smarter Analyst (NASDAQ:IONS) www.smarteranalyst.com - September 23 at 8:36 AM
	Ionis Pharma's (IONS) Akcea Announces Publication of Encouraging Lp(a)-Lowering Drug Data (NASDAQ:IONS) www.streetinsider.com - September 22 at 3:42 PM
	Akcea Announces Publication in The Lancet of Clinical Results with Lp(a)-Lowering Drugs Designed to Treat Cardiovascular Dise... (NASDAQ:IONS) www.advfn.com - September 22 at 3:42 PM
	Biogen Bets on Nusinersen (BIIB, IONS) (NASDAQ:IONS) www.investopedia.com - September 22 at 3:42 PM
	Analysts Take the Wheel on Ionis Pharmaceuticals Inc (NASDAQ:IONS) Shares and Where They Might Be Headed - Frisco Fastball (NASDAQ:IONS) friscofastball.com - September 22 at 8:52 AM
	Ionis Pharma's (IONS) Akcea Announces Publication of Encouraging Lp(a)-Lowering Drug Data - StreetInsider.com (NASDAQ:IONS) www.streetinsider.com - September 22 at 8:52 AM
	Akcea Announces Publication in The Lancet of Clinical Results with Lp(a)-Lowering Drugs Designed to Treat Cardiovascular Disease (NASDAQ:IONS) www.publicnow.com - September 22 at 8:51 AM
	Moves in Cancer Therapeutics among Recent Developments for Ionis (NASDAQ:IONS) marketrealist.com - September 22 at 8:51 AM
	Stock on the Move- Ionis Pharmaceuticals, Inc.'s (IONS) - Hot Stocks Point (NASDAQ:IONS) www.hotstockspoint.com - September 21 at 3:53 PM
	Concerns Diverting Active Stocks Direction: Medtronic (NYSE:MDT), Ionis Pharmaceuticals, Inc. (IONS), AmSurg (AMSG) - Street Wise Report (press release) (blog) (NASDAQ:IONS) streetwisereport.com - September 16 at 9:35 AM
	Ionis Pharmaceuticals' (IONS) Management presents at 2016 Wells Fargo Healthcare Brokers Conference Transcript - Seeking Alpha (NASDAQ:IONS) seekingalpha.com - September 15 at 6:05 PM
	ETF’s with exposure to Ionis Pharmaceuticals, Inc. : September 15, 2016 (NASDAQ:IONS) www.capitalcube.com - September 15 at 6:05 PM
	Could Ionis Pharmaceuticals Inc Decline After Today's Huge Increase? - Chester News (NASDAQ:IONS) www.chesterindependent.com - September 15 at 8:52 AM
	Akcea Therapeutics Announces Presentations of New Data Underscoring Burden of Disease in Familial Chylomicronemia Syndrome (NASDAQ:IONS) www.publicnow.com - September 15 at 8:52 AM
	HC Stocks Impression= Cytori Therapeutics Inc (CYTX), Ionis Pharmaceuticals Inc (NASDAQ:IONS) - share market updates (press release) (NASDAQ:IONS) sharemarketupdates.com - September 14 at 9:53 AM
	Ionis Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IONS-US : September 12, 2016 (NASDAQ:IONS) www.capitalcube.com - September 14 at 9:53 AM
	Ionis Pharmaceuticals, Inc. – Value Analysis (NASDAQ:IONS) : September 13, 2016 (NASDAQ:IONS) www.capitalcube.com - September 14 at 9:53 AM
	Jefferies Group Increases Adeptus Health Inc. (ADPT) Price Target to $100.00 (NASDAQ:IONS) myhealthbowl.com - September 9 at 5:26 PM
	Ionis Pharmaceuticals, Inc. (IONS) (NASDAQ:IONS) finance.yahoo.com - September 7 at 9:04 AM
	Research Reports on Healthcare Equities -- Endo, Teva Pharma Industries, Ionis Pharma, and Catalent (NASDAQ:IONS) www.bizjournals.com - September 7 at 9:04 AM
	News Analysis Report: Ionis Pharmaceuticals Inc (NASDAQ:IONS), LyondellBasell Industries NV(NYSE:LYB), Mattel ... - NYSE Journal (press release) (NASDAQ:IONS) stockznews.com - September 6 at 10:25 AM
	Ionis Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IONS-US : September 2, 2016 (NASDAQ:IONS) www.capitalcube.com - September 2 at 10:28 AM
	Upcoming Earnings Report: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - The Voice Registrar (NASDAQ:IONS) voiceregistrar.com - September 1 at 5:32 PM
	$IONS & $KOS - Ionis Pharmaceuticals Inc (NASDAQ:IONS) & Kosmos Energy Ltd (NYSE:KOS) Stocks in the Spotlight - Money News (NASDAQ:IONS) www.newsismoney.com - September 1 at 5:32 PM
	Ionis Pharmaceuticals : to Present at Upcoming Investor Conferences (NASDAQ:IONS) www.4-traders.com - September 1 at 8:38 AM
	Traders Recap: Ionis Pharmaceuticals Inc (NASDAQ:IONS), Prudential Financial Inc (NYSE:PRU), Home Depot Inc ... - NYSE Journal (press release) (NASDAQ:IONS) stockznews.com - August 30 at 8:52 AM
	Equities Trend Analysis: Ionis Pharmaceuticals, Inc. (IONS), Coach ... - iStreetWire (NASDAQ:IONS) istreetwire.com - August 26 at 5:31 PM
	Stocks in the News: Oclaro, Inc. (NASDAQ:OCLR), Ionis Pharmaceuticals Inc (NASDAQ:IONS) - NYSE Journal (press release) (NASDAQ:IONS) stockznews.com - August 25 at 10:41 AM
	Ionis Pharmaceuticals, Inc.'s (IONS): Momentum Stock in Focus - Hot Stocks Point (NASDAQ:IONS) www.hotstockspoint.com - August 25 at 10:41 AM
	Stocks Highlights: Danaher (DHR), Ionis Pharmaceuticals (IONS), Capital One Financial (COF) - iStreetWire (NASDAQ:IONS) istreetwire.com - August 23 at 10:02 AM
	Ionis Pharmaceuticals Inc. (NASDAQ: IONS) Outperform Rating Reiterated at Wells Fargo & Co. - BNB Daily (blog) (NASDAQ:IONS) www.baseball-news-blog.com - August 23 at 10:02 AM
	ISIS Pharmaceuticals : Ionis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives E. B. Hershberg Award from the American Chemical Society (NASDAQ:IONS) www.4-traders.com - August 22 at 10:16 AM
	Ionis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives E. B. Hershberg Award from the American Chemical Society (NASDAQ:IONS) www.publicnow.com - August 22 at 10:16 AM
	The Key Numbers To Watch From Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)'s Earnings - The Voice Registrar (NASDAQ:IONS) voiceregistrar.com - August 19 at 8:38 AM
	Ionis Pharmaceuticals Inc. (NASDAQ: IONS) Overweight Rating Reiterated at Piper Jaffray Cos. - BNB Daily (blog) (NASDAQ:IONS) www.baseball-news-blog.com - August 19 at 8:38 AM
	Wells Fargo Boosts Valuation Range on Ionis Pharmaceuticals Inc (IONS); Here's Why - Smarter Analyst (NASDAQ:IONS) www.smarteranalyst.com - August 19 at 8:38 AM
	Wells Fargo Boosts Valuation Range on Ionis Pharmaceuticals Inc (IONS); Here’s Why (NASDAQ:IONS) www.smarteranalyst.com - August 18 at 5:41 PM
	IONIS PHARMACEUTICALS INC Financials (NASDAQ:IONS) finance.yahoo.com - August 18 at 5:41 PM
	Ionis Pharmaceuticals Inc Begins to Shift Focus (NASDAQ:IONS) www.fool.com - August 16 at 5:50 PM
	Piper Jaffray Positive on Ionis Pharmaceuticals Inc (IONS); Sees Bright Future Ahead - Smarter Analyst (NASDAQ:IONS) www.smarteranalyst.com - August 16 at 12:19 PM
	Piper Jaffray Positive on Ionis Pharmaceuticals Inc (IONS); Sees Bright Future Ahead (NASDAQ:IONS) www.smarteranalyst.com - August 15 at 9:13 PM